phenylalanine has been researched along with Dry Eye Syndromes in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (75.00) | 24.3611 |
| 2020's | 6 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barabino, S; Cohen, A; Donnenfeld, E; Figueiredo, FC; Holland, EJ; Jackson, MA; Piccolo, R; Rolando, M | 1 |
| Lin, MC; Neri, P; Perez, VL; Periman, LM; Saban, DR | 1 |
| Evans, DG; Karpecki, PM; Nichols, KK | 1 |
| Mathew, R; Perez, VL; Saban, DR; Singh, PP; Yu, C | 1 |
| Baillif, S; Elmaleh, V; Ferrete, T; Loschi, M; Martel, A; Rocher, F; Tieulie, N | 1 |
| Asbell, PA; Kuklinski, E | 1 |
| Finn, LA; Hussar, DA | 1 |
| Donnenfeld, ED; Nattis, AS; Perry, HD; Rosenberg, ED | 1 |
| de Paiva, CS; Guimaraes de Souza, R; Pflugfelder, SC; Stern, ME; Yu, Z | 1 |
| Kang, S; Kim, CE; Kim, K; Kleinman, HK; Ousler, GW; Sosne, G; Yang, J | 1 |
| Donnenfeld, ED; Hovanesian, JA; Karpecki, PM; Nichols, KK; Raychaudhuri, A; Shojaei, A; Zhang, S | 1 |
| Akpek, EK; Amescua, G; Dunn, SP; Farid, M; Garcia-Ferrer, FJ; Lin, A; Mah, FS; Musch, DC; Rhee, MK; Varu, DM | 1 |
| Chan, CC; Prokopich, CL | 1 |
| Gupta, PK; Passi, SF; Tong, AY | 1 |
| D'Ambrosio, FA; Eiferman, RA; Kennedy, KS; Lonsdale, JD; McLaurin, EB; Semba, CP; Sheppard, JD; Torkildsen, GL | 1 |
| Corrales, RM; de Paiva, CS; Krauss, AH; Pelegrino, FS; Pflugfelder, SC; Tukler-Henriksson, J | 1 |
| Karpecki, P; Latkany, R; Luchs, J; Martel, J; Raychaudhuri, A; Sall, K; Semba, CP; Smith, V; Tauber, J | 1 |
| Contreras-Ruiz, L; Krauss, AH; Masli, S; Mir, FA; Turpie, B | 1 |
| Haque, R; Perez, VL; Pflugfelder, SC; Shojaei, A; Zhang, S | 1 |
| Donnenfeld, ED; Karpecki, PM; Majmudar, PA; Nichols, KK; Raychaudhuri, A; Roy, M; Semba, CP | 1 |
| Paton, DM | 1 |
| Keating, GM | 1 |
| Holland, EJ; Jackson, MA; Karpecki, PM; Luchs, J; Nichols, KK; Raychaudhuri, A; Roy, M; Sall, K; Shojaei, A; Tauber, J | 1 |
8 review(s) available for phenylalanine and Dry Eye Syndromes
| Article | Year |
|---|---|
The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
Topics: Administration, Topical; Clinical Decision-Making; Cyclosporine; Dry Eye Syndromes; Goblet Cells; Homeostasis; Humans; Immunologic Factors; Immunosuppressive Agents; Inflammation; Integrins; Intercellular Adhesion Molecule-1; Lacrimal Apparatus; Lymphocyte Function-Associated Antigen-1; Phenylalanine; Steroids; Sulfones; T-Lymphocytes; Tears | 2020 |
A Comprehensive Review of the Clinical Trials Conducted for Dry Eye Disease and the Impact of the Vehicle Comparators in These Trials.
Topics: Administration, Ophthalmic; Clinical Trials as Topic; Cyclosporine; Dry Eye Syndromes; Emulsions; Humans; Ophthalmic Solutions; Pharmaceutical Vehicles; Phenylalanine; Sulfones | 2021 |
Sjogren's syndrome from the perspective of ophthalmology.
Topics: Administration, Ophthalmic; Cyclosporine; Dry Eye Syndromes; Fatty Acids, Omega-3; Glucocorticoids; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Muscarinic Agonists; Ophthalmology; Phenylalanine; Pilocarpine; Punctal Plugs; Quinuclidines; Sjogren's Syndrome; Sulfones; Thiophenes | 2017 |
Lifitegrast for the treatment of dry eye disease in adults.
Topics: Adult; Clinical Trials as Topic; Dry Eye Syndromes; Humans; Lymphocyte Function-Associated Antigen-1; Ophthalmic Solutions; Phenylalanine; Quality of Life; Sulfones; Treatment Outcome | 2017 |
Dry Eye Syndrome Preferred Practice Pattern®.
Topics: Academies and Institutes; Cyclosporine; Diagnostic Techniques, Ophthalmological; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Ophthalmology; Phenylalanine; Physical Examination; Practice Patterns, Physicians'; Sulfones; United States | 2019 |
Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program.
Topics: Animals; Clinical Trials as Topic; Dry Eye Syndromes; Humans; Ophthalmic Solutions; Phenylalanine; Sulfones; Treatment Outcome | 2019 |
Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.
Topics: Cell Adhesion; Dry Eye Syndromes; Humans; Intercellular Adhesion Molecule-1; Lymphocyte Function-Associated Antigen-1; Phenylalanine; Sulfones | 2016 |
Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
Topics: Dry Eye Syndromes; Humans; Ophthalmic Solutions; Phenylalanine; Sulfones | 2017 |
5 trial(s) available for phenylalanine and Dry Eye Syndromes
| Article | Year |
|---|---|
Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Sulfones; Treatment Outcome; Visual Analog Scale | 2019 |
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Conjunctiva; Cornea; Double-Blind Method; Dry Eye Syndromes; Female; Fluorescein; Fluorometry; Humans; Lissamine Green Dyes; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Staining and Labeling; Sulfones; Treatment Outcome; Young Adult | 2014 |
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Topics: Adult; Aged; Aged, 80 and over; Cornea; Double-Blind Method; Dry Eye Syndromes; Female; Humans; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Sulfones; Tears; Treatment Outcome; Visual Acuity; Visual Analog Scale; Young Adult | 2015 |
Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Dry Eye Syndromes; Female; Fluorophotometry; Humans; Intraocular Pressure; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Sulfones; Visual Acuity; Young Adult | 2016 |
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Topics: Adult; Aged; Double-Blind Method; Dry Eye Syndromes; Eye Pain; Female; Humans; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Sulfones; Visual Acuity | 2017 |
11 other study(ies) available for phenylalanine and Dry Eye Syndromes
| Article | Year |
|---|---|
Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials.
Topics: Double-Blind Method; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Randomized Controlled Trials as Topic; Sulfones; Treatment Outcome | 2021 |
Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model.
Topics: Animals; Dry Eye Syndromes; Eyelid Diseases; Humans; Hypersensitivity; Immunity; Lymphocyte Function-Associated Antigen-1; Meibomian Gland Dysfunction; Meibomian Glands; Mice; Phenylalanine; Sulfones; Tears | 2021 |
Eye amputation following lifitegrast treatment for ocular graft-versus-host disease: First case report.
Topics: Aged; Amputation, Surgical; Dry Eye Syndromes; Graft vs Host Disease; Humans; Phenylalanine; Sulfones | 2021 |
2017 New Drug Update.
Topics: Anti-Inflammatory Agents; Antipsychotic Agents; Drugs, Investigational; Dry Eye Syndromes; Gout Suppressants; Humans; Hypoglycemic Agents; Insulin, Long-Acting; Peptides; Phenylalanine; Piperidines; Sulfones; Thioglycolates; Triazoles; Urea | 2017 |
Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast.
Topics: Animals; Chemokine CXCL11; Chemokine CXCL9; Dry Eye Syndromes; Female; Inflammation; Interferon-gamma; Keratoconjunctivitis Sicca; Mice; Mice, Inbred C57BL; Ophthalmic Solutions; Phenylalanine; Sulfones; Th1 Cells | 2018 |
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
Topics: Animals; Conjunctiva; Cornea; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Female; Goblet Cells; Humans; Inflammation Mediators; Lacrimal Apparatus; Male; Mice; Mice, Inbred NOD; Mucins; Ophthalmic Solutions; Phenylalanine; Polyphosphates; Prescription Drugs; Scopolamine; Sulfones; Tears; Thymosin; Treatment Outcome; Uracil Nucleotides | 2018 |
Clinical Outcomes of Lifitegrast 5% Ophthalmic Solution in the Treatment of Dry Eye Disease.
Topics: Adult; Aged; Aged, 80 and over; Conjunctiva; Cornea; Dose-Response Relationship, Drug; Dry Eye Syndromes; Female; Follow-Up Studies; Humans; Lymphocyte Function-Associated Antigen-1; Male; Matrix Metalloproteinase 9; Middle Aged; Ophthalmic Solutions; Phenylalanine; Retrospective Studies; Sulfones; Tears; Treatment Outcome; Young Adult | 2020 |
Improvement of Outcome Measures of Dry Eye by a Novel Integrin Antagonist in the Murine Desiccating Stress Model.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Biomarkers; Cell Adhesion; Cells, Cultured; Cornea; Dendritic Cells; Disease Models, Animal; Dry Eye Syndromes; Female; Flow Cytometry; Integrin alpha Chains; Integrin alpha4; Integrin alpha4beta1; Leukocytes; Mice; Mice, Inbred C57BL; Organic Chemicals; Phenylalanine; Piperidines; Vascular Cell Adhesion Molecule-1 | 2015 |
Sjögren's syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090.
Topics: Administration, Topical; Animals; Cell Count; Dexamethasone; Disease Models, Animal; Dry Eye Syndromes; Fluorescein; Glucocorticoids; Goblet Cells; Integrin alpha4beta1; Interleukin-1beta; Mice; Mice, Inbred C57BL; Nuclear Receptor Subfamily 1, Group F, Member 3; Ophthalmic Solutions; Phenylalanine; Piperidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sjogren's Syndrome; Staining and Labeling; Thrombospondin 1 | 2016 |
Lifitegrast (Xiidra) for dry eye disease.
Topics: Administration, Ophthalmic; Anti-Inflammatory Agents; Drug Administration Schedule; Dry Eye Syndromes; Humans; Lymphocyte Function-Associated Antigen-1; Ophthalmic Solutions; Phenylalanine; Sulfones; Treatment Outcome | 2016 |
Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
Topics: Anti-Inflammatory Agents; Clinical Studies as Topic; Drug Evaluation, Preclinical; Dry Eye Syndromes; Humans; Inflammation; Intercellular Adhesion Molecule-1; Lymphocyte Function-Associated Antigen-1; Ophthalmic Solutions; Phenylalanine; Sulfones; T-Lymphocytes | 2016 |